GeneHealth - Your precision medicine

Branched-chain Keto Acid Dehydrogenase Kinase Deficiency

Disease Details

Family Health Simplified

Buy Membership

Description: Branched-chain keto acid dehydrogenase kinase deficiency is a rare metabolic disorder that impairs the body's ability to break down certain amino acids, leading to their accumulation and potential neurological damage.
Type: Branched-chain keto acid dehydrogenase kinase deficiency is a metabolic disorder that primarily affects the breakdown of certain amino acids. It is inherited in an autosomal recessive manner. This means a person must inherit two copies of the defective gene, one from each parent, to be affected by the disorder.
Signs And Symptoms: BCKDK deficit disease symptoms may include autism, intellectual disability and developmental delay.
R.Constante, Juliana et al. reported a list of symptoms in a study of 20 cases.
Those symptoms included: neurodevelopmental delay, gross motor function impairment, intellectual disability, language impairment, epilepsy and clumsiness, and also microcephaly, non present at birth.
Prognosis: Branched-chain keto acid dehydrogenase kinase deficiency, also known as BCKDK deficiency, is a rare genetic disorder characterized by elevated levels of branched-chain amino acids due to a defect in the BCKDK gene. Prognosis varies and can include developmental delays, neurological issues, and other symptoms. Early diagnosis and dietary management, specifically a controlled intake of branched-chain amino acids, can improve outcomes. However, the long-term prognosis remains individualized.
Onset: Branched-chain keto acid dehydrogenase kinase deficiency typically presents in infancy or early childhood. The symptoms may include neurological and developmental issues, often identified through metabolic testing or genetic screening.
Prevalence: Branched-chain ketoacid dehydrogenase kinase deficiency is an extremely rare metabolic disorder. Prevalence data is not well-documented, but it is considered to be a very rare condition, with only a few cases reported in the medical literature.
Epidemiology: Branched-chain keto acid dehydrogenase kinase deficiency (BCKDK deficiency) is an extremely rare metabolic disorder. Because of its rarity, detailed epidemiological data are limited. The available information suggests that the condition has been diagnosed in only a few individuals worldwide. Due to its rare nature, specific prevalence rates are not well established.
Intractability: Branched-chain ketoacid dehydrogenase kinase deficiency, often leading to a condition known as Maple Syrup Urine Disease (MSUD), can be challenging to manage but is not necessarily intractable. The condition requires strict dietary management to limit the intake of branched-chain amino acids (leucine, isoleucine, and valine). With consistent medical supervision, dietary modifications, and, in some cases, supplementation with appropriate medical formulas, individuals with this deficiency can manage symptoms and complications effectively. Early diagnosis and adherence to treatment protocols are critical for better outcomes.
Disease Severity: Branched-chain keto acid dehydrogenase kinase deficiency typically results in a mild form of Maple Syrup Urine Disease (MSUD). This variant often presents with fewer symptoms compared to classic MSUD, but can still include episodes of metabolic decompensation under stress or illness. Regular monitoring and dietary management can help manage the condition effectively.
Healthcare Professionals: Disease Ontology ID - DOID:0090126
Pathophysiology: Branched-chain keto acid dehydrogenase kinase (BCKDK) deficiency is a metabolic disorder that affects the catabolism of branched-chain amino acids (BCAAs)—leucine, isoleucine, and valine. The primary pathophysiology of BCKDK deficiency involves a dysfunction in the regulation of the branched-chain α-keto acid dehydrogenase complex (BCKD complex), which is crucial for the breakdown of BCAAs.

In BCKDK deficiency, there is a lack of BCKDK enzyme activity, leading to the constant activation of the BCKD complex. This results in the excessive degradation of BCAAs, and subsequently lower levels of these essential amino acids in the body. The deficiency in BCAAs can lead to a variety of symptoms, including developmental delay, intellectual disability, and neurological issues, due to their critical roles in brain function, protein synthesis, and other metabolic pathways.
Carrier Status: Branched-chain keto acid dehydrogenase kinase deficiency (BCKDK deficiency) is inherited in an autosomal recessive manner. This means that a person would need to inherit two defective copies of the BCKDK gene, one from each parent, to manifest the disease. If a person has only one defective copy of the gene, they are considered a carrier. Carriers typically do not show symptoms of the disease but can pass the defective gene to their offspring.
Mechanism: Branched-chain keto acid dehydrogenase kinase (BCKDK) deficiency is a rare metabolic disorder affecting the regulation of the branched-chain α-keto acid dehydrogenase (BCKDH) complex, which is crucial in the catabolism of branched-chain amino acids (BCAAs) such as leucine, isoleucine, and valine.

**Mechanism:**
BCKDK deficiency leads to the hyperactivity of the BCKDH complex, which is normally regulated by the kinase (BCKDK). BCKDK phosphorylates and inactivates the BCKDH complex, thereby reducing BCAA catabolism. When BCKDK is deficient, the BCKDH complex remains largely dephosphorylated and consequently overactive, leading to excessive breakdown of BCAAs.

**Molecular Mechanisms:**
1. **Gene Mutation:** BCKDK deficiency is caused by mutations in the BCKDK gene, which encodes the branched-chain keto acid dehydrogenase kinase.
2. **Biochemical Pathway:** Normally, BCKDK phosphorylates the E1 component of the BCKDH complex, reducing its activity. In the absence of functional BCKDK due to genetic mutations, this regulation is impaired.
3. **Metabolic Impact:** The unregulated BCKDH complex leads to continuously high activity levels, resulting in accelerated degradation of BCAAs into their respective keto acids and further downstream products.
4. **Physiological Consequences:** Excessive catabolism of BCAAs may result in reduced plasma and tissue levels of these essential amino acids, potentially leading to metabolic imbalances and clinical symptoms such as developmental delays, neurological issues, and muscle wasting.

Understanding these molecular mechanisms is critical for developing targeted treatments, which may include dietary management and potential gene therapies to correct the underlying enzymatic deficiency.
Treatment: Continuous replenishment of BCAA levels has been reported to alleviate the symptoms in patients, combined with a high protein diet.
Ongoing studies, not yet published, may indicate a greater improvement if the supplementation is administrated every 3 hours.
When treatment was applied, (supplementation of 100–260 mg/kg/day and high protein diet), all patients improved in motor functions, and half the patients reached normocephaly.
None of the patients that started treatment before 2 years old developed autism, and the patient who started treatment earlier (8 months) experienced almost normal development at 3 years old.
Compassionate Use Treatment: For branched-chain keto acid dehydrogenase kinase (BCKDK) deficiency, compassionate use treatments and experimental or off-label therapies are usually considered when conventional treatment options are limited or ineffective. This might include:

1. **Dietary Interventions**: A high-protein diet may be administered to manage symptoms, as dietary management is crucial in metabolic disorders.

2. **Amino Acid Supplementation**: Supplementation with branched-chain amino acids (BCAAs) like leucine, isoleucine, and valine may help to correct metabolic imbalances caused by the deficiency.

3. **Gene Therapy**: Although still largely experimental, gene therapy is a potential future avenue for treating metabolic disorders caused by enzyme deficiencies.

4. **Pharmacological Chaperones**: These are small molecules that stabilize the defective enzyme, possibly restoring some functionality. They remain experimental for many rare enzyme deficiencies.

Physicians managing BCKDK deficiency should always consider the latest clinical trials and emerging research for potential new treatments.
Lifestyle Recommendations: For branched-chain keto acid dehydrogenase kinase deficiency (BCKDK deficiency), lifestyle recommendations primarily focus on dietary management:

1. **Low-Protein Diet**: Since this condition affects the metabolism of branched-chain amino acids (leucine, isoleucine, and valine), individuals may benefit from a low-protein diet to reduce the intake of these amino acids.

2. **Frequent Monitoring**: Regular follow-up with a healthcare provider, including blood tests to monitor amino acid levels, is crucial to manage the condition effectively.

3. **Specialized Medical Foods**: In some cases, specially formulated medical foods that are low in specific amino acids may be recommended to control levels in the blood.

4. **Supplementation**: Depending on individual cases, certain vitamin or mineral supplements may be advised to support overall health.

5. **Avoiding Fasting**: Long periods of fasting can exacerbate symptoms; regular, balanced meals help maintain stable blood sugar and amino acid levels.

6. **Physical Activity**: Light to moderate exercise can be beneficial, but it should be discussed with a healthcare provider to ensure it is safe and appropriate.

Regular consultation with a dietitian familiar with metabolic disorders is highly recommended to tailor dietary plans to individual needs.
Medication: Branched-chain keto acid dehydrogenase kinase deficiency, also known as BCKDK deficiency, is a rare metabolic disorder that affects the regulation of branched-chain amino acids (BCAAs). There is no specific medication approved exclusively for this deficiency. The primary management strategy typically involves dietary modifications to regulate BCAA levels in the blood. This might include a protein-restricted diet to limit the intake of BCAAs and regular monitoring by a metabolic specialist. In some cases, supplementation with specific nutrients or amino acids may be recommended based on the individual's metabolic needs. Treatment plans are generally tailored to each patient's unique condition and symptoms.
Repurposable Drugs: There are currently no well-established repurposable drugs specifically for branched-chain keto acid dehydrogenase kinase deficiency (BCKDK deficiency). Treatment typically focuses on managing symptoms and adhering to a carefully regulated diet to control the levels of branched-chain amino acids. Research is ongoing, and consultation with a medical specialist who is knowledgeable about metabolic disorders is recommended for the most up-to-date therapeutic options.
Metabolites: Branched-chain keto acid dehydrogenase kinase (BCKDK) deficiency is a metabolic disorder that affects the breakdown of branched-chain amino acids (BCAAs). In this condition, the BCKDK enzyme, which normally inhibits the branched-chain alpha-keto acid dehydrogenase complex (BCKD), is deficient. As a result, there is excessive activity of BCKD, leading to abnormally low levels of BCAAs, such as leucine, isoleucine, and valine, in the blood. Elevated levels of their corresponding keto acids might also be observed.
Nutraceuticals: There are no well-established nutraceutical treatments specifically for branched-chain keto acid dehydrogenase kinase (BCKDK) deficiency. Management typically involves dietary regulation to control leucine levels. Consultation with a healthcare provider is essential for personalized management and potential intervention strategies.
Peptides: Branched-chain keto-acid dehydrogenase kinase deficiency (BCKDK deficiency) is a rare metabolic disorder characterized by the body's inability to properly regulate the degradation of branched-chain amino acids (BCAAs): leucine, isoleucine, and valine. This results in the overactivity of the branched-chain α-keto acid dehydrogenase complex (BCKD), leading to decreased levels of these essential amino acids in the blood. Proper diagnosis and management usually involve biochemical tests and genetic confirmation. Treatment often includes dietary supplementation of BCAAs to maintain adequate levels. Peptides and non-standard amino acids (nan) are not specifically noted as part of the typical management or characterization of this deficiency.